These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 9710882)

  • 1. The use of Neoral in rheumatoid arthritis.
    Cranney A; Tugwell P
    Rheum Dis Clin North Am; 1998 Aug; 24(3):479-88. PubMed ID: 9710882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoral--new cyclosporin for old?
    Somerville MF; Scott DG
    Br J Rheumatol; 1997 Oct; 36(10):1113-5. PubMed ID: 9374930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conversion of patients with rheumatoid arthritis from the conventional to a microemulsion formulation of cyclosporine: a double blind comparison to screen for differences in safety, efficacy, and pharmacokinetics.
    Anderson IF; Helve T; Hannonen P; Leirisalo-Repo M; Gilboe IM; Nissilä M; Keystone EC; Kraag GR; Bjørneboe O; Chalmers A; Dovland H; Mueller E; Richard F; Whatmough I; Schmidt AG; Kovarik JM
    J Rheumatol; 1999 Mar; 26(3):556-62. PubMed ID: 10090162
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microemulsion formulation of cyclosporin (Sandimmun Neoral) vs Sandimmun: comparative safety, tolerability and efficacy in severe active rheumatoid arthritis. On behalf of the OLR 302 Study Group.
    Yocum DE; Allard S; Cohen SB; Emery P; Flipo RM; Goobar J; Jayawardena S; Job-Deslandre C; Jubb RW; Krüger K; Lopes Vaz A; Manger B; Mur E; Nygaard H; Weiner SM; Rainer F; Sack MR; Schiff MH; Schnitzer TJ; Trigg LB; Whatmough I; Schmidt AG
    Rheumatology (Oxford); 2000 Feb; 39(2):156-64. PubMed ID: 10725065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical use of cyclosporin in rheumatoid arthritis.
    Richardson C; Emery P
    Drugs; 1995; 50 Suppl 1():26-36. PubMed ID: 8714796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. International consensus recommendations on cyclosporin use in rheumatoid arthritis.
    Tugwell P
    Drugs; 1995; 50 Suppl 1():48-56. PubMed ID: 8714799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and tolerability of conversion from stable Sandimmun maintenance treatment to Sandimmun Neoral in patients with rheumatoid arthritis.
    Flipo RM; Emery P; Scott DG; Situnayake RD; Prowse PJ; James DW; Cawley MI; Whatmough I; Schmidt AG
    J Rheumatol; 1998 Jul; 25(7):1263-9. PubMed ID: 9676754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety aspects of cyclosporin in rheumatoid arthritis.
    Dijkmans BA
    Drugs; 1995; 50 Suppl 1():41-7. PubMed ID: 8714798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of cyclosporine in pediatric long-term liver transplant recipients converted from Sandimmun to Neoral.
    Melter M; Rodeck B; Kardorff R; Hoyer PF; Brodehl J
    Transpl Int; 1997; 10(6):419-25. PubMed ID: 9428114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and tolerability of a new oral formulation of cyclosporin A, Sandimmun Neoral, in renal transplant patients.
    Taesch S; Niese D
    Transpl Int; 1994; 7 Suppl 1():S263-6. PubMed ID: 11271220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclosporine microemulsion increases drug exposure and reduces acute rejection without incremental toxicity in de novo renal transplantation. International Sandimmun Neoral Study Group.
    Keown P; Niese D
    Kidney Int; 1998 Sep; 54(3):938-44. PubMed ID: 9734620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclosporine and tacrolimus for the treatment of rheumatoid arthritis.
    Kitahara K; Kawai S
    Curr Opin Rheumatol; 2007 May; 19(3):238-45. PubMed ID: 17414949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Variability of the bioavailability of cyclosporine: benefit of the Neoral formulation].
    Humbert H
    Therapie; 1997; 52(4):353-7. PubMed ID: 9437891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relative bioavailability of a new oral form of cyclosporin A in patients with rheumatoid arthritis.
    van den Borne BE; Landewé RB; Goei The HS; Mattie H; Breedveld FC; Dijkmans BA
    Br J Clin Pharmacol; 1995 Feb; 39(2):172-5. PubMed ID: 7742156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclosporin. A review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral).
    Noble S; Markham A
    Drugs; 1995 Nov; 50(5):924-41. PubMed ID: 8586033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation.
    Dunn CJ; Wagstaff AJ; Perry CM; Plosker GL; Goa KL
    Drugs; 2001; 61(13):1957-2016. PubMed ID: 11708766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of a new microemulsion formulation of cyclosporin A (Neoral) in young patients after renal transplantation.
    Krmar RT; Wühl E; Ding R; Aulmann M; Schärer K
    Transpl Int; 1996; 9(5):476-80. PubMed ID: 8875790
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation.
    Mueller EA; Kovarik JM; van Bree JB; Tetzloff W; Grevel J; Kutz K
    Pharm Res; 1994 Feb; 11(2):301-4. PubMed ID: 8165192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Absorption of cyclosporin from conventional and new microemulsion oral formulations in liver transplant recipients with external biliary diversion.
    Trull AK; Tan KK; Tan L; Alexander GJ; Jamieson NV
    Br J Clin Pharmacol; 1995 Jun; 39(6):627-31. PubMed ID: 7654480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neoral (Cyclosporin microemulsion preconcentrate): pharmacokinetics, pharmacodynamics and its improved clinical outcome].
    Nishi Y
    Nihon Yakurigaku Zasshi; 2001 Aug; 118(2):107-15. PubMed ID: 11530680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.